Equity Details
Price & Market Data
Price: $5.26
Daily Change: +$0.06 / 1.14%
Daily Range: $5.03 - $5.30
Market Cap: $335,131,616
Daily Volume: 536,712
Performance Metrics
1 Week: -3.00%
1 Month: -9.12%
3 Months: 3.19%
6 Months: -24.82%
1 Year: 335.3%
YTD: -21.28%
About Immuneering Corporation (IMRX)
Stay informed with Immuneering Corporation (IMRX) market data. Current price: 5.26, daily change: +$0.06 / 1.14%. Market cap: 335,131,616. Performance over 1-month, 3-month, and 1-year.
Company Details
Employees: 37
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.